DDU validates drug candidates and patient subgroups for neuropsychiatric and neurodevelopmental disorders through observational studies and investigational trials. DDU combines expertise in operations, medicine, drug and clinical development, to bring STALICLA’s clinical-stage treatment options closer to patients.
DDS applies AI-driven and systems biology precision medicine approaches to patient data sets. Bringing together computational biologists, human geneticists, data scientists, chemo-informaticians and developers, DDS ensures that STALICLA’s first-in-class DEPI technology is producing next-generation therapeutics for NDDs.
CEO and Founder
Chief Scientific and Clinical Development Advisor/Medical Officer, DDU
Head of Discovery, Deputy Head of Discovery and Data Science Unit, DDS
Chief Technology Officer, Head of Discovery and Data Science Unit, DDS
Head of Clinical Science, DDU
Head of Clinical Operations, DDU
Chief Financial Officer, DDU
Chief of Staff, DDU
CEO and Founder
Member
Observer
Rush University
Cincinnati Children’s Hospital
UCLA
Yale School of Medicine
Nationwide Children's Hospital